Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Oklo has a large cash cushion and a high-profile advanced-nuclear story, but the filings still show a pre-revenue company whose investment case depends on licensing, deployment, fuel, customers and capital discipline converting into real power economics.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
A source-backed ENPH deep dive covering Q1 2026 revenue, margins, tariffs, cash flow, short interest, IQ9S, PowerMatch, GaN, IQ SST, and the proof gates that decide whether Enphase is a cyclical recovery or still a solar reset story.
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAcumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
OpenTag facets appear after tag usage counts are rebuilt.